Journal profile · BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
Nucleic Acid Therapeutics
ISSN 2159-3337 · eISSN 2159-3345 · Mary Ann Liebert Inc. · UNITED STATES · Founded 2011
Nucleic Acid Therapeutics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.48; hybrid open access; review over 12 weeks (community reports); community-reported acceptance: easy; 34 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Nucleic Acid Therapeutics is published by Mary Ann Liebert Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques and DNA and Nucleic Acid Chemistry, together about 55.2% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.
Source: LetPub
Research area (LetPub): BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
Main research topics OpenAlex counts of recent articles; shares are approximate
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology26.1%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology19.5%
- DNA and Nucleic Acid ChemistryBiochemistry, Genetics and Molecular Biology9.6%
- RNA and protein synthesis mechanismsBiochemistry, Genetics and Molecular Biology5.7%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology5.7%
- RNA Research and SplicingBiochemistry, Genetics and Molecular Biology4.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.7%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.48LetPub ·
- CiteScore 2026-06
- 11.4LetPub ·
- SJR 2026-06
- 1.95LetPub ·
- SNIP 2026-06
- 1.19LetPub ·
- h-index
- 61LetPub ·
- h-index
- 64OpenAlex ·
- i10-index
- 408OpenAlex ·
- 2-year mean citedness
- 4.93OpenAlex ·
- Self-citation rate
- 6.7%LetPub ·
- Share of gold OA articles
- 36.14%LetPub ·
Volume
- Articles per year
- 29LetPub ·
Articles by year OpenAlex count · 636 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 17 | 4 | 5 |
| 2025 | 34 | 19 | 120 |
| 2024 | 33 | 22 | 289 |
| 2023 | 26 | 15 | 403 |
| 2022 | 42 | 23 | 946 |
| 2021 | 42 | 23 | 1,021 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Founded
- 2011
- ISSN
- 2159-3337
- Electronic ISSN
- 2159-3345
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Nucleic Acid Therapeutics
What CAS zone is Nucleic Acid Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nucleic Acid Therapeutics is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Chemistry, Medicinal / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nucleic Acid Therapeutics?
The latest impact factor listed by LetPub is 4.48; CiteScore 11.4, h-index 64.
How long does peer review take at Nucleic Acid Therapeutics?
Authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Nucleic Acid Therapeutics?
According to LetPub and DOAJ records, Nucleic Acid Therapeutics is indexed in SCIE and Scopus.
Is Nucleic Acid Therapeutics open access, and what is the APC?
Nucleic Acid Therapeutics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .